Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
The Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.
Ongoing education and proven outcomes need to aid this form of testing.
This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.
The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.
Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.
Here is a review of using this therapy in this patient population.
The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.
Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.
Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.
This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.
Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?
Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.
The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.
A cautious approach for now is warranted as well as a need for a randomized clinical trial.
For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.
On the heels of the first death in an ongoing US-based measles outbreak, Paul Offit, MD, discusses how outbreaks are the first sign that childhood vaccination rates are starting to decline.